Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes
- 6 November 2020
- journal article
- editorial
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (1), e9-e11
- https://doi.org/10.2337/dc20-1073
Abstract
No abstract availableFunding Information
- Canadian Institutes of Health Research (FDN-143328)
This publication has 5 references indexed in Scilit:
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2019
- Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United KingdomEpidemiology, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes MellitusCurrent Diabetes Reports, 2012